Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Utility of Nexium in Chronic Cough and Reflux Disease

NCT00287339
View directory record Official record
Conditions
Cough, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Type 2 Diabetes Mellitus

NCT00871572
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2409021, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Buena Park, California • Huntington Park, California • Westlake Village, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

NCT01738451
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436 75 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 24, 2026, 2:08 AM EDT
Recruiting Phase 4 Interventional

Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients

NCT07561541
View directory record Official record
Conditions
Fracture Lower Leg, Diabetes, Fracture Fixation, Internal
Interventions
Cefadroxil 500 mg Capsules, Clindamycin, Bactrim DS
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Los Angeles, California • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Opioid Modulation and Neural Reward Activation in Healthy Adults

NCT04854551
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use, Unspecified
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129
View directory record Official record
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

NCT01250366
View directory record Official record
Conditions
HCV (Genotype 1)
Interventions
INX-08189, Placebo matching with INX-08189, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

NCT02680756
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
Interventions
Ferric Maltol, Ferric Carboxy Maltose
Drug
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Dothan, Alabama • Tucson, Arizona • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Nortriptyline for Idiopathic Gastroparesis

NCT00765895
View directory record Official record
Conditions
Idiopathic Gastroparesis
Interventions
Nortriptyline Hydrochloride, Placebo (for nortriptyline)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
San Francisco, California • Stanford, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 24, 2026, 2:08 AM EDT
Terminated Phase 4 Interventional

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

NCT07053475
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions
Ferric Carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
Syed Hamza Mufarrih
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bowling Green, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 24, 2026, 2:08 AM EDT
Recruiting Early Phase 1 Interventional

Fecal Microbiota Transplantation in Kidney Stone Patients

NCT05516472
View directory record Official record
Conditions
Kidney Stones
Interventions
Microbial Transplant Therapy, Placebo
Drug
Lead sponsor
Joshua Stern
Other
Eligibility
18 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Park City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

NCT01400412
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03561701
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 24, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

NCT06993155
View directory record Official record
Conditions
Semen Quality
Interventions
Leflutrozole, Dose 1, Leflutrozole, Dose 2, Leflutrozole, Dose 3, Placebo
Drug
Lead sponsor
ReproNovo Aps
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
North Hollywood, California • Pomona, California • Garden City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Reduction of Breast Cancer Risk

NCT00917735
View directory record Official record
Conditions
Breast Cancer
Interventions
Green tea extract supplement, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
1,075 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
5
States / cities
Edina, Minnesota • Maple Grove, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 24, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ongoing Lung Decline With Age Intensified Response

NCT07676435
View directory record Official record
Conditions
Age-Related Lung Function Decline
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia

NCT00611806
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, B12, Placebo
Dietary Supplement · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 24, 2026, 2:08 AM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor

NCT00848172
View directory record Official record
Conditions
Essential Tremor
Interventions
Octanoic Acid, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 24, 2026, 2:08 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Theophylline for Depression Study

NCT04309877
View directory record Official record
Conditions
Depression
Interventions
Theophylline ER, PO placebo, Lipopolysaccharide (LPS), IV placebo
Drug · Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT03260205
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
48
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 24, 2026, 2:08 AM EDT